Neurizon Therapeutics has completed enrolment for Regimen I of its HEALEY ALS Platform Trial in under five months, speeding up topline data release to late Q2 2027 and materially de-risking its lead clinical program.
- 250 participants enrolled in record time for Regimen I
- Topline efficacy and safety results now expected late Q2 2027
- Trial expansion from 160 to 240 participants amid strong recruitment
- Completion reduces execution risk for NUZ-001 program
- Participants progressing through 36-week randomised treatment phase
Record-Breaking Recruitment Accelerates Trial Timeline
Neurizon Therapeutics (ASX:NUZ) has blitzed through enrolment for Regimen I of the HEALEY ALS Platform Trial, signing up 250 participants in under five months from first dosing. This makes it the fastest recruitment phase in the trial’s history, even after the sample size was expanded from 160 to 240 to capitalise on strong momentum. The rapid pace has allowed Neurizon to bring forward the anticipated topline efficacy and safety results to late Q2 CY2027, shaving months off previous expectations.
De-Risking a Late-Stage ALS Clinical Program
The completion of enrolment marks a significant milestone for Neurizon’s lead drug candidate NUZ-001, a late-stage investigational therapy targeting amyotrophic lateral sclerosis (ALS). With all participants now commencing treatment and progressing through a planned 36-week randomised controlled phase, the company has materially reduced execution risk for this pivotal clinical program. The HEALEY ALS Platform Trial is widely regarded as a leading global initiative, and the accelerated recruitment underscores both operational efficiency and strong investigator engagement across numerous US clinical sites.
Collaborative Effort Across a Premier ALS Trial Network
The trial’s success owes much to the infrastructure of the HEALEY ALS Platform Trial, conducted by the Sean M. Healey & AMG Center at Mass General Brigham in partnership with the Network of Excellence for ALS (NEALS). The next-generation master protocol has streamlined site activation and participant screening, enabling this swift enrolment. Neurizon’s Interim Executive Chairman, Sergio Duchini, praised the dedication of patients, families, and clinical teams, noting that their commitment is vital to advancing new treatment options for ALS.
Looking Ahead to Data and Development Milestones
As participants move through the randomised treatment and subsequent extension phases, all eyes will be on the topline efficacy and safety readout expected in late Q2 2027. This accelerated timeline offers an important near-term catalyst for Neurizon and its shareholders, potentially shaping the commercial and regulatory pathway for NUZ-001. The company’s focus now shifts to maintaining operational discipline and delivering robust trial execution through to data release.
Bottom Line?
Neurizon’s rapid enrolment in the HEALEY ALS trial accelerates a key data milestone, setting the stage for a critical readout in mid-2027 that could reshape its clinical trajectory.
Questions in the middle?
- Will the accelerated enrolment translate into faster regulatory review or approval timelines for NUZ-001?
- How might the expanded participant cohort impact the statistical power and interpretation of trial results?
- What are the implications for Neurizon’s commercial strategy if the topline data meet expectations?